| Medical and Health Sciences | Lifetime | 643 | ES 6 | 99.97 |
| Medical and Health Sciences | 2021-2025 | 30 | ES 1 | 99.99 |
| Pulmonary and Respiratory Medicine | Lifetime | 33 | ES 1 | 99.96 |
| Oncology | Lifetime | 49 | ES 1 | 99.92 |
| Cancer Research | Lifetime | 608 | ES 8 | 95.92 |
| Otolaryngology | Lifetime | 575 | ES 8 | 82.22 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 2 | ES 1 | 99.98 |
| Oncology | 2021-2025 | 3 | ES 1 | 99.98 |
| Cancer Research | 2021-2025 | 72 | ES 1 | 96.75 |
| Radiology, Nuclear Medicine and Imaging | 2021-2025 | 475 | ES 5 | 90.42 |
| Lung Cancer Diagnosis and Treatment | Lifetime | 6 | ES 1 | 99.94 |
| Lung Cancer Treatments and Mutations | Lifetime | 10 | ES 1 | 99.95 |
| Lung Cancer Research Studies | Lifetime | 11 | ES 1 | 99.93 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 30 | ES 1 | 99.91 |
| Colorectal Cancer Treatments and Studies | Lifetime | 71 | ES 3 | 99.68 |
| Cancer Genomics and Diagnostics | Lifetime | 140 | ES 2 | 99.68 |
| Peptidase Inhibition and Analysis | Lifetime | 174 | ES 5 | 99.20 |
| Cancer therapeutics and mechanisms | Lifetime | 135 | ES 4 | 99.12 |
| Pancreatic and Hepatic Oncology Research | Lifetime | 368 | ES 4 | 99.01 |
| Cancer Diagnosis and Treatment | Lifetime | 270 | ES 3 | 98.42 |
| HER2/EGFR in Cancer Research | Lifetime | 235 | ES 5 | 98.95 |
| Neuroendocrine Tumor Research Advances | Lifetime | 380 | ES 4 | 98.60 |
| Pleural and Pulmonary Diseases | Lifetime | 311 | ES 5 | 97.42 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 477 | ES 13 | 96.50 |
| Ferroptosis and cancer prognosis | Lifetime | 687 | ES 5 | 93.89 |
| Multiple and Secondary Primary Cancers | Lifetime | 436 | ES 5 | 95.90 |
| Occupational and environmental lung diseases | Lifetime | 435 | ES 5 | 95.65 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 1 | ES 1 | 99.99 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 2 | ES 1 | 99.98 |
| Lung Cancer Research Studies | 2021-2025 | 2 | ES 2 | 99.96 |
| Lung Cancer Diagnosis and Treatment | 2021-2025 | 3 | ES 1 | 99.94 |
| Cancer Genomics and Diagnostics | 2021-2025 | 20 | ES 1 | 99.75 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 26 | ES 2 | 99.66 |
| Peptidase Inhibition and Analysis | 2021-2025 | 42 | ES 6 | 99.02 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 86 | ES 6 | 97.89 |
| Pancreatic and Hepatic Oncology Research | 2021-2025 | 151 | ES 4 | 98.45 |
| Cancer therapeutics and mechanisms | 2021-2025 | 42 | ES 2 | 96.65 |
| Gastric Cancer Management and Outcomes | 2021-2025 | 315 | ES 5 | 97.32 |
| HER2/EGFR in Cancer Research | 2021-2025 | 122 | ES 8 | 98.17 |
| CAR-T cell therapy research | 2021-2025 | 683 | ES 32 | 95.99 |
| Pleural and Pulmonary Diseases | 2021-2025 | 102 | ES 3 | 93.44 |
| Multiple and Secondary Primary Cancers | 2021-2025 | 95 | ES 2 | 91.43 |
| Neuroendocrine Tumor Research Advances | 2021-2025 | 376 | ES 13 | 92.78 |
| Occupational and environmental lung diseases | 2021-2025 | 123 | ES 4 | 91.86 |
| Brain Metastases and Treatment | 2021-2025 | 313 | ES 4 | 92.08 |
| Immunotherapy and Immune Responses | 2021-2025 | 1,000 | ES 19 | 90.73 |
| Cancer Diagnosis and Treatment | 2021-2025 | 682 | ES 9 | 77.84 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 300 | ES 4 | 77.73 |
| Advances in Oncology and Radiotherapy | 2021-2025 | 556 | ES 8 | 76.97 |
| Melanoma and MAPK Pathways | 2021-2025 | 836 | ES 28 | 70.12 |
| Protein Tyrosine Phosphatases | 2021-2025 | 478 | ES 13 | 56.55 |
